Our Phase 3 SERENITY-CM study will be initiating in 2023
© 2022 Sollis Therapeutics Inc.
Sollis Therapeutics is a registered trademark of Sollis Therapeutics, Inc.
Terms of Use | Privacy Policy
Design and development by RainCastle Communications
Patients need new approaches to treating sciatica pain.
Clinicians seek new interventions for treating sciatica pain.
We’re working to redefine interventional pain treatment for sciatica.
At Sollis, we’re developing an investigational therapy to treat patients for whom conservative sciatica pain treatments have been ineffective.
Developing a new approach to treating sciatica pain
Our Clonidine Micropellet (clonidine hydrochloride extended-release epidural micropellet) investigational treatment is designed to target the source of sciatica pain over time, while also reducing inflammation at the injured nerve.* Our goal is to develop rapid, durable pain relief that allows healing—using a non-opioid, non-steroid medication.
Explore Sollis Clinical Trials
Study Summaries & Clinical Evidence
Learn more about clinical trials and review results and publications.
Upcoming Trials
We are currently in the planning stages for upcoming trials. Check back soon for up-to-date information.
* The Sollis Clonidine Micropellet therapy is an investigational treatment for sciatica and has not been approved for use by the FDA.